Psoriasis is a chronic autoimmune disease affecting millions worldwide, characterized by raised, red, scaly patches on the skin. These patches, often itchy and painful, can significantly impact a person's quality of life, both physically and emotionally. Moderate-to-severe plaque psoriasis, the most common form of the disease, presents a significant challenge for patients and healthcare providers alike.

Psoriasis, a chronic autoimmune condition affecting millions worldwide, can feel like a relentless battle. The constant itching, the inflamed skin, the emotional toll – it's a lot to bear. But amidst the challenges, there's always hope for new and better treatments. Recently, Johnson & Johnson announced promising results from their Phase III trial of icotrokinra, a potential game-changer for those living with plaque psoriasis.